Burchill, S A <br/><br/>
Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.  [electronic resource] 

 -  Medical and pediatric oncology  Jan 2001 
 - 213-9 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0098-1532 
<br/><br/><label>Standard No.: </label>10.1002/1096-911X(20010101)36:1<213::AID-MPO1052>3.0.CO;2-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--genetics<br/>Child<br/>Child, Preschool<br/>Combined Modality Therapy<br/>Hematopoietic Stem Cell Mobilization<br/>Hematopoietic Stem Cell Transplantation--adverse effects<br/>Humans<br/>Infant<br/>Life Tables<br/>Neoplasm Proteins--genetics<br/>Neoplasm, Residual<br/>Neoplastic Cells, Circulating<br/>Neuroblastoma--blood<br/>RNA, Messenger--blood<br/>RNA, Neoplasm--blood<br/>Remission Induction<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Sensitivity and Specificity<br/>Survival Analysis<br/>Transplantation, Autologous--adverse effects<br/>Treatment Outcome<br/>Tumor Cells, Cultured--chemistry<br/>Tyrosine 3-Monooxygenase--genetics